Science Moves Closer to Predicting Alzheimer’s

There is encouraging news in the fight against Alzheimer’s disease. Scientists have developed a new blood test that may help predict when memory symptoms are likely to begin — sometimes years before they appear. For older adults and families concerned about brain health, this is an important step forward.

According to the U.S. Food and Drug Administration (FDA), about 10% of people age 65 and older have Alzheimer’s disease, and that number is expected to grow in the coming decades.

Alzheimer’s disease is a progressive brain disorder that slowly damages memory, thinking, and daily functioning. It is the most common form of dementia.

Changes in the brain can begin 10 to 20 years before noticeable memory problems appear. One key sign of Alzheimer’s is the buildup of amyloid plaques in the brain. Until recently, detecting these early changes required expensive brain scans or spinal fluid tests.

On May 16, 2025, the U.S. Food and Drug Administration cleared the first blood test to help diagnose Alzheimer’s disease.

The test, called Lumipulse G PTau217 / β-Amyloid 1-42 Plasma Ratio, measures two proteins in the blood — pTau217 and beta-amyloid 1-42. Changes in these protein levels are linked to the development of amyloid plaques in the brain.

This test is intended for adults age 55 and older who are already showing signs or symptoms of memory problems. It does not predict the exact day symptoms will begin, but research suggests it may help estimate how close someone is to developing them.

Some researchers describe it as a “memory timeline.” Higher levels of certain proteins may signal that Alzheimer’s-related changes have started in the brain.

Although this test is not yet part of routine checkups, it offers several potential benefits:

While research continues, there are proven ways to support brain health:

Not long ago, a simple blood test to help predict Alzheimer’s symptoms seemed impossible. Today, it is becoming reality. While more research is needed, this breakthrough offers hope for earlier answers, better treatment, and a future where Alzheimer’s may feel less uncertain.

For now, staying informed and proactive about your health remains the best strategy. Science is moving forward — and with it, the possibility of earlier answers, better treatments, and a future where Alzheimer’s may no longer feel so unpredictable.

Who is the new Alzheimer’s blood test intended for?

The FDA-cleared test is designed for adults age 55 and older who are already experiencing signs or symptoms of memory problems.

What does the test actually measure?

It measures the ratio of two specific proteins in the blood: pTau217 and beta-amyloid 1-42, which are linked to the buildup of amyloid plaques in the brain.

Can the test predict exactly when I will develop Alzheimer’s?

No, it does not provide an exact date. Instead, it helps create a “memory timeline” to estimate how close someone might be to developing symptoms.

How does this differ from previous testing methods?

Previously, detecting early brain changes required more invasive or expensive procedures, such as spinal fluid tests or specialized brain scans.

× How can I help you?